Charles River Laboratories International (CRL) EBIAT: 2009-2025
Historic EBIAT for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $55.6 million.
- Charles River Laboratories International's EBIAT fell 20.97% to $55.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year decrease of 118.60%. This contributed to the annual value of $25.3 million for FY2024, which is 94.74% down from last year.
- Charles River Laboratories International's EBIAT amounted to $55.6 million in Q3 2025, which was up 5.43% from $52.7 million recorded in Q2 2025.
- In the past 5 years, Charles River Laboratories International's EBIAT ranged from a high of $189.1 million in Q4 2022 and a low of -$213.7 million during Q4 2024.
- Its 3-year average for EBIAT is $58.2 million, with a median of $74.5 million in 2024.
- Per our database at Business Quant, Charles River Laboratories International's EBIAT spiked by 48.94% in 2022 and then tumbled by 213.12% in 2024.
- Charles River Laboratories International's EBIAT (Quarterly) stood at $139.8 million in 2021, then surged by 35.24% to $189.1 million in 2022, then decreased by 0.08% to $189.0 million in 2023, then tumbled by 213.12% to -$213.7 million in 2024, then fell by 20.97% to $55.6 million in 2025.
- Its EBIAT stands at $55.6 million for Q3 2025, versus $52.7 million for Q2 2025 and $25.9 million for Q1 2025.